{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:56:42Z","timestamp":1790755002879,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01414-z","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:02:04Z","timestamp":1790751724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Options for Recurrent Abdominal Low-grade Well-differentiated Liposarcoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Anna","family":"Boulouta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Digklia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Stergioula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Kyriazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1414_CR1","unstructured":"Menon G, Kaur A. Liposarcoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 [cited 2026 Aug 1]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK538265\/ PubMed PMID: 30855853."},{"issue":"8","key":"1414_CR2","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.3390\/ijerph17082710","volume":"17","author":"S Bock","year":"2020","unstructured":"Bock S, Hoffmann DG, Jiang Y, Chen H, Il\u2019yasova D. Increasing Incidence of Liposarcoma: A Population-Based Study of National Surveillance Databases, 2001\u20132016. Int J Environ Res Public Health. 2020;17(8):2710. https:\/\/doi.org\/10.3390\/ijerph17082710 . PubMed PMID: 32326423; PubMed Central PMCID: PMC7215751.","journal-title":"Int J Environ Res Public Health"},{"key":"1414_CR3","unstructured":"Springfield D. Liposarcoma. PubMed [Internet]. [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/8472432\/"},{"key":"1414_CR4","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1038\/s41598-025-85937-9","volume":"15","author":"J Zhao","year":"2025","unstructured":"Zhao J, Du W, Tao X, Li A, Li Y, Zhang S. Survival and prognostic factors among different types of liposarcomas based on SEER database. Sci Rep. 2025;15:1790. https:\/\/doi.org\/10.1038\/s41598-025-85937-9 . PubMed PMID: 39805922; PubMed Central PMCID: PMC11729850.","journal-title":"Sci Rep"},{"issue":"1","key":"1414_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41416-024-02674-y","volume":"132","author":"AJ Hayes","year":"2025","unstructured":"Hayes AJ, Nixon IF, Strauss DC, Seddon BM, Desai A, Benson C, et al. UK guidelines for the management of soft tissue sarcomas. Br J Cancer. 2025;132(1):11\u201331. https:\/\/doi.org\/10.1038\/s41416-024-02674-y.","journal-title":"Br J Cancer"},{"key":"1414_CR6","unstructured":"Bonvalot S, Gronchi A, Le P\u00e9choux C, Swallow C, Strauss D, Meeus P et al. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. PubMed [Internet]. [cited 2026 Aug 26]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32941794\/"},{"key":"1414_CR7","unstructured":"Callegaro D, Raut C, Ajayi T, Bonvalot DS, Ng S. D, Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC-62092 Trial (STRASS) versus off-trial (STREXIT) results. PubMed [Internet]. 2023 [cited 2026 Aug 26]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35833413\/"},{"key":"1414_CR8","doi-asserted-by":"publisher","first-page":"107327482098302","DOI":"10.1177\/1073274820983028","volume":"28","author":"A Sobiborowicz","year":"2021","unstructured":"Sobiborowicz A, Spa\u0142ek MJ, Czarnecka AM, Rutkowski P. Definitive Radiotherapy in the Management of Non-Resectable or Residual Retroperitoneal Sarcomas: Institutional Cohort Analysis and Systematic Review. Cancer Control. 2021;28:1073274820983028. doi:10.1177\/1073274820983028 PubMed PMID: 33567904; PubMed Central PMCID: PMC8482705.","journal-title":"Cancer Control"},{"key":"1414_CR9","doi-asserted-by":"crossref","unstructured":"Babatunde O, Seier K, Schwartz G, Keohan M, D\u2019Angelo S, Gounder M et al. Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated\/dedifferentiated liposarcoma. PubMed [Internet]. [cited 2026 Jul 31]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/41864163\/","DOI":"10.1016\/j.esmoop.2026.106899"},{"key":"1414_CR10","unstructured":"Binh M, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagac\u00e9 R et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. PubMed [Internet]. [cited 2026 Aug 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16160477\/"},{"key":"1414_CR11","unstructured":"Lee A, Thway K, Huang P, Jones R, Clinical and molecular spectrum of liposarcoma. PubMed [Internet]. 2018 [cited 2026 Jul 31]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29220294\/"},{"issue":"3","key":"1414_CR12","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","volume":"76","author":"W Wang","year":"2024","unstructured":"Wang W, Albadari N, Du Y, Fowler JF, Sang HT, Xian W, et al. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. Pharmacol Rev. 2024;76(3):414\u201353. https:\/\/doi.org\/10.1124\/pharmrev.123.001026 . PubMed PMID: 38697854; PubMed Central PMCID: PMC11068841.","journal-title":"Pharmacol Rev"},{"key":"1414_CR13","unstructured":"Pilotti S, Della Torre G, Lavarino C, Di Palma S, Sozzi G, Minoletti F et al. Distinct mdm2\/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. PubMed [Internet]. [cited 2026 Aug 24]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/9071998\/"},{"key":"1414_CR14","unstructured":"Assi T, Kattan J, Rassy E, Nassereddine H, Farhat F, Honore C et al. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review. PubMed [Internet]. [cited 2026 Aug 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32593094\/"},{"key":"1414_CR15","unstructured":"Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, Bompas E et al. Advanced well-differentiated\/dedifferentiated liposarcomas: role of chemotherapy and survival. PubMed [Internet]. [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22039081\/"},{"key":"1414_CR16","unstructured":"Judson I, Verweij J, Gelderblom H, Hartmann J, Sch\u00f6ffski P, Blay J et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. PubMed [Internet]. [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24618336\/"},{"key":"1414_CR17","doi-asserted-by":"crossref","unstructured":"Maki R, Wathen J, Patel S, Priebat D, Okuno S, Samuels B et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. PubMed [Internet]. 2007 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/17602081\/","DOI":"10.1200\/JCO.2006.10.4117"},{"key":"1414_CR18","unstructured":"Thirasastr P, Lin H, Amini B, Wang W, Cloutier J, Nassif E et al. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. PubMed [Internet]. [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36151848\/"},{"key":"1414_CR19","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Del-Muro X, L\u00f3pez-Pousa A, Maurel J, Mart\u00edn J, Mart\u00ednez-Trufero J, Casado A et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. PubMed [Internet]. 2011 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21606430\/","DOI":"10.1200\/JCO.2010.33.6107"},{"key":"1414_CR20","unstructured":"Fabbroni C, Grignani G, Vincenzi B, Fumagalli E, De Pas T, Mazzocca A et al. TRAbectedin in adVanced rEtroperitoneal well differentiated\/dedifferentiated Liposarcoma and Leiomyosarcoma (TRAVELL): results of a phase II study from the Italian Sarcoma Group. PubMed [Internet]. [cited 2026 Jul 31]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39121815\/"},{"key":"1414_CR21","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ffski P, Chawla S, Maki R, Italiano A, Gelderblom H, Choy E et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. PubMed [Internet]. 2016 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26874885\/","DOI":"10.1016\/S0140-6736(15)01283-0"},{"key":"1414_CR22","unstructured":"Demetri G, Sch\u00f6ffski P, Grignani G, Blay J, Maki R, Van Tine B et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III Study of eribulin versus dacarbazine. PubMed [Internet]. 2017 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28854066\/"},{"issue":"29","key":"1414_CR23","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1038\/s41388-020-1354-9","volume":"39","author":"V Wagner","year":"2020","unstructured":"Wagner V, Gil J. Senescence as a therapeutically relevant response to CDK4\/6 inhibitors. Oncogene. 2020;39(29):5165\u201376. https:\/\/doi.org\/10.1038\/s41388-020-1354-9 . PubMed PMID: 32541838; PubMed Central PMCID: PMC7610384.","journal-title":"Oncogene"},{"key":"1414_CR24","doi-asserted-by":"crossref","unstructured":"Dickson M, Tap W, Keohan M, D\u2019Angelo S, Gounder M, Antonescu C et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. PubMed [Internet]. 2013 [cited 2026 Jul 31]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/23569312\/","DOI":"10.1200\/JCO.2012.46.5476"},{"key":"1414_CR25","doi-asserted-by":"crossref","unstructured":"Dickson M, Schwartz G, Keohan M, D\u2019Angelo S, Gounder M, Chi P et al. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial. PubMed [Internet]. 2016 [cited 2026 Jul 31]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27124835\/","DOI":"10.1001\/jamaoncol.2016.0264"},{"key":"1414_CR26","unstructured":"Klein M, Dickson M, Antonescu C, Qin L, Dooley S, Barlas A et al. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4\/6 inhibitor therapy-induced senescence. PubMed [Internet]. [cited 2026 Aug 18]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29789718\/"},{"issue":"17suppl","key":"1414_CR27","doi-asserted-by":"publisher","first-page":"LBA2","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA2","volume":"44","author":"MA Dickson","year":"2026","unstructured":"Dickson MA, Ballman KV, Weiss MC, Attia S, Wagner MJ, Pollack SM, et al. SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma. J Clin Oncol. 2026;44(17suppl):LBA2\u20132. https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA2.","journal-title":"J Clin Oncol"},{"key":"1414_CR28","unstructured":"Sarcoma Alliance for Research through Collaboration. SARC041. Phase 3 Randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma [Clinical trial registration] [Internet]. clinicaltrials.gov; 2024 Dec [cited 2026 Aug 18]. Clinical trial registration no.: NCT04967521. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04967521"},{"key":"1414_CR29","doi-asserted-by":"crossref","unstructured":"Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. PubMed [Internet]. 2006 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16443686\/","DOI":"10.1073\/pnas.0507493103"},{"key":"1414_CR30","doi-asserted-by":"crossref","unstructured":"Gounder M, Bauer T, Schwartz G, Weise A, LoRusso P, Kumar P et al. A first-in-human phase I Study of milademetan, an MDM2 inhibitor, in patients with advanced liposarcoma, solid tumors, or lymphomas. PubMed [Internet]. 2023 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36669146\/","DOI":"10.1200\/JCO.22.01285"},{"issue":"16suppl","key":"1414_CR31","doi-asserted-by":"publisher","first-page":"TPS11589","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS11589","volume":"40","author":"MM Gounder","year":"2022","unstructured":"Gounder MM, Schwartz GK, Jones RL, Chawla SP, Chua-Alcala VS, Stacchiotti S, et al. MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas. J Clin Oncol. 2022;40(16suppl):TPS11589\u201311589. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS11589.","journal-title":"J Clin Oncol"},{"key":"1414_CR32","unstructured":"Reichardt P, Sch\u00f6ffski P, Lorusso P, Yamamoto N, Garcia VM, Lugowska I et al. 61MO Phase Ia\/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: Overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS) [Internet]. [cited 2026 Aug 1]. Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(24)00219-9\/fulltext"},{"key":"1414_CR33","doi-asserted-by":"crossref","unstructured":"Gollner A, Rudolph D, Weyer-Czernilofsky U, Baumgartinger R, Jung P, Weinstabl H et al. Discovery and Characterization of brigimadlin, a novel and highly potent MDM2-p53 antagonist suitable for intermittent dose schedules. PubMed [Internet]. 2024 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39259562\/","DOI":"10.1158\/1535-7163.32715142"},{"issue":"8","key":"1414_CR34","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","volume":"13","author":"P LoRusso","year":"2023","unstructured":"LoRusso P, Yamamoto N, Patel MR, Laurie SA, Bauer TM, Geng J, et al. The MDM2\u2013p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study. Cancer Discov. 2023;13(8):1802\u201313. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0153 . PubMed PMID: 37269344; PubMed Central PMCID: PMC10401071.","journal-title":"Cancer Discov"},{"key":"1414_CR35","doi-asserted-by":"publisher","unstructured":"Sch\u00f6ffski P, Sanfilippo R, Mart\u00edn-Broto J, Kawai A, Desai J, LoRusso P, et al. Brigimadlin versus doxorubicin in advanced dedifferentiated liposarcoma: efficacy, safety, and translational data from brightline-1, a randomized phase II\/III Trial. Clin Cancer Res. 2026;OF1\u201314. https:\/\/doi.org\/10.1158\/1078-0432.CCR-26-0509.","DOI":"10.1158\/1078-0432.CCR-26-0509"},{"key":"1414_CR36","doi-asserted-by":"crossref","unstructured":"Abdul Razak A, Bauer S, Suarez C, Lin C, Quek R, H\u00fctter-Kr\u00f6nke M et al. Co-targeting of MDM2 and CDK4\/6 with siremadlin and ribociclib for the treatment of patients with well-differentiated or dedifferentiated liposarcoma: Results from a proof-of-concept, phase Ib study. PubMed [Internet]. 2022 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34921024\/","DOI":"10.1158\/1078-0432.CCR-21-1291"},{"key":"1414_CR37","unstructured":"Brahmi M, Tredan O, Gomez-Roca CA, Italiano A, Saada EB, Bertucci F et al. LBA80 Siremadlin (S) and ribociclib (R) in patients (pt) with advanced well-differentiated\/dedifferentiated liposarcomas (WD\/DD LPS) and other molecularly selected cancers: Final analysis of the MEGAMOST Ribociclib\/HDM201 basket study [Internet]. [cited 2026 Aug 1]. Available from: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(24)03903-6\/fulltext"},{"key":"1414_CR38","doi-asserted-by":"publisher","unstructured":"Vargas AC, Maclean FM, Sioson L, Tran D, Bonar F, Mahar A et al. Prevalence of PD-L1 expression in matched recurrent and\/or metastatic sarcoma samples and in a range of selected sarcomas subtypes [Internet]. https:\/\/doi.org\/10.1371\/journal.pone.0222551","DOI":"10.1371\/journal.pone.0222551"},{"key":"1414_CR39","doi-asserted-by":"crossref","unstructured":"Haddox C, Nathenson M, Mazzola E, Lin J, Baginska J, Nau A et al. Phase II study of eribulin plus pembrolizumab in metastatic soft-tissue sarcomas: Clinical outcomes and biological correlates. PubMed [Internet]. 2024 [cited 2026 Jul 31]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38236580\/","DOI":"10.1158\/1078-0432.25515970.v1"},{"key":"1414_CR40","unstructured":"Tawbi HA, Burgess M, Bolejack V, Tine BAV, Schuetze SM, Hu J et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial [Internet]. [cited 2026 Aug 20]. Available from: https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(17)30624-1\/abstract"},{"key":"1414_CR41","doi-asserted-by":"crossref","unstructured":"Wilky B, Trucco M, Subhawong T, Florou V, Park W, Kwon D et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. PubMed [Internet]. [cited 2026 Aug 20]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31078463\/","DOI":"10.1016\/S1470-2045(19)30153-6"},{"key":"1414_CR42","unstructured":"Keung E, Burgess M, Salazar R, Parra E, Rodrigues-Canales J, Bolejack V et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab. PubMed [Internet]. 2020 [cited 2026 Aug 20]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31900276\/"},{"issue":"6","key":"1414_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3892\/ol.2022.13303","volume":"23","author":"A Kyriazoglou","year":"2022","unstructured":"Kyriazoglou A, Gkaralea LE, Kotsantis I, Anastasiou M, Pantazopoulos A, Prevezanou M, et al. Tyrosine kinase inhibitors in sarcoma treatment. Oncol Lett. 2022;23(6):183. https:\/\/doi.org\/10.3892\/ol.2022.13303 . PubMed PMID: 35527786; PubMed Central PMCID: PMC9073578.","journal-title":"Oncol Lett"},{"key":"1414_CR44","doi-asserted-by":"crossref","unstructured":"Chen T, Hsu C, Hong R, Lee J, Chang K, Yu C et al. A single-arm phase Ib\/II study of lenvatinib plus eribulin in advanced liposarcoma and leiomyosarcoma. PubMed [Internet]. 2022 [cited 2026 Aug 1]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36129471\/","DOI":"10.1158\/1078-0432.c.6533006.v1"},{"issue":"15","key":"1414_CR45","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1158\/0008-5472.CAN-22-3173","volume":"83","author":"MP Ludwig","year":"2023","unstructured":"Ludwig MP, Galbraith MD, Eduthan NP, Hill AA, Clay MR, Tellez CM, et al. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4\/CHOP Stress Response Pathway. Cancer Res. 2023;83(15):2543\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-22-3173 . PubMed PMID: 37205634; PubMed Central PMCID: PMC10391328.","journal-title":"Cancer Res"},{"issue":"833","key":"1414_CR46","doi-asserted-by":"publisher","first-page":"eadw4689","DOI":"10.1126\/scitranslmed.adw4689","volume":"18","author":"EM Pimenta","year":"2026","unstructured":"Pimenta EM, Garza AE, Camp SY, Park J, Hoffman SE, Valderr\u00e1bano L, et al. Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. Sci Transl Med. 2026;18(833):eadw4689. https:\/\/doi.org\/10.1126\/scitranslmed.adw4689.","journal-title":"Sci Transl Med"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01414-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01414-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01414-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:02:15Z","timestamp":1790751735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01414-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1414"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01414-z","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"26 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"48"}}